The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
This lengthy study with the drug Mounjaro seems to point to even better success than they’d hoped. Eli Lilly, the mind behind ...
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Unlike Ozempic, Wegovy is approved for weight management even though they both contain semaglutide. However, they do have ...
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
A voguish — and often daunting — problem can plague people who have experienced recent and relatively rapid weight loss.